Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) hit a new 52-week low during trading on Friday . The stock traded as low as $78.56 and last traded at $78.62, with a volume of 1020052 shares traded. The stock had previously closed at $82.16.

Several analysts have recently commented on the company. Zacks Investment Research cut BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. BidaskClub raised BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 16th. JPMorgan Chase & Co. decreased their target price on BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating for the company in a research report on Wednesday, January 24th. Wedbush reaffirmed an “outperform” rating and issued a $110.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, December 22nd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $114.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, January 18th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $111.60.

The stock has a market capitalization of $14,430.00, a PE ratio of -96.38 and a beta of 1.71. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.

In other BioMarin Pharmaceutical news, Director Elaine J. Heron sold 800 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $88.90, for a total value of $71,120.00. Following the completion of the sale, the director now owns 38,385 shares of the company’s stock, valued at $3,412,426.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP George Eric Davis sold 30,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $90.66, for a total value of $2,719,800.00. Following the completion of the sale, the executive vice president now directly owns 112,942 shares of the company’s stock, valued at approximately $10,239,321.72. The disclosure for this sale can be found here. Insiders sold 90,750 shares of company stock valued at $8,159,588 in the last ninety days. Insiders own 1.85% of the company’s stock.

Large investors have recently made changes to their positions in the business. First Manhattan Co. lifted its position in shares of BioMarin Pharmaceutical by 104.2% in the fourth quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock worth $109,000 after buying an additional 625 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of BioMarin Pharmaceutical by 12.9% in the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock worth $193,000 after buying an additional 243 shares during the last quarter. Commerce Bank acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter worth about $209,000. IFG Advisory LLC acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth about $212,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter worth about $220,000. 98.83% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “BioMarin Pharmaceutical (BMRN) Hits New 12-Month Low at $78.56” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/02/09/biomarin-pharmaceutical-bmrn-hits-new-12-month-low-at-78-56.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.